Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 2/3 2Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 5Unknown 1

Sponsor Class

NIH 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Thalidomide × Clear all
NCT00006016 2015-04-15

Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00276705 2013-09-17

Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
47 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00058487 2013-07-18

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00006006 2013-02-11

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

National Cancer Institute (NCI)

Phase 2 Completed
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00519688 2011-10-17

UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 2 Completed
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00250796 2010-01-07

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

University of New Mexico

Phase 2 Completed
12 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡